Hirose Electric Co Stock (OTC:HROEY), Trade Ideas

Hirose Electric Co Ltd is a Japan-based company that manufactures and distributes electrical and electronic connectors for use in automotive, mobile communication, telecommunications, networking, and smart grid applications. Its product portfolio includes printed circuit boards, optical connectors, fiber optic cables, sealed connectors, microwave components, switches and sensors, modular jacks and plugs, integrated circuit cards and sockets, and coaxial cables. The firm generates revenue in Europe, Asia, and North America.

HIROSE ELECTRIC UNSP/ADR by Hirose Electric

Hirose Electric Co Ltd

<div>Expects to deliver adjusted operating margin of&nbsp;22.5%&nbsp;-&nbsp;23.5%&nbsp;for the full year 2024,&nbsp;approximately&nbsp;$88 million&nbsp;in non-cash pension income for the full year 2024</div>

News

Guidance

Willis Towers Watson Still Expects To Deliver 2024 Revenue Of $9.9B Or Greater (Est $10.024B) And Mid-Single Digit Organic Revenue Growth, Adjusted EPS Of $15.40-$17.00 (Est $16.28)

<div>Revenue less repair payments&#x2A; is expected to be between&nbsp;$1,293&nbsp;million and&nbsp;$1,357&nbsp;million, up from&nbsp;$1,284.3&nbsp;million in fiscal 2024.&nbsp;Guidance&nbsp;assumes an average GBP to USD exchange rate of 1.27 versus 1.26 in fiscal 2024. ANI&#x2A; is expected to range between&nbsp;$206 million&nbsp;and&nbsp;$218 million&nbsp;versus&nbsp;$217.0 million&nbsp;in fiscal 2024.&nbsp;Guidance&nbsp;assumes an average USD to INR exchange rate of 83.0 versus 82.8 in fiscal 2024. Based on a diluted share count of 47.5 million shares, the company expects fiscal 2025 adjusted diluted earnings per share&#x2A; to be in the range of&nbsp;$4.34&nbsp;to&nbsp;$4.59&nbsp;versus&nbsp;$4.38&nbsp;in fiscal 2024.</div>
&quot;The company has provided our initial forecast for fiscal 2025 based on current visibility levels and exchange rates,&quot; said Sanjay Puria, WNS&#39; Chief Financial Officer. &quot;Our&nbsp;guidance&nbsp;for the full year reflects growth in revenue less repair payments&#x2A; of&nbsp;1%&nbsp;to&nbsp;6%&nbsp;on a reported&#x2A; basis, and&nbsp;0%&nbsp;to&nbsp;5%&nbsp;on a constant currency&#x2A; basis. For the year, we continue to expect capital expenditures of up to&nbsp;$65 million.&quot;

WNS (Holdings) Says It Expects FY25 Revenue Of $1.293B-$1.357B Vs. $1.36B Estimate; Projects FY25 Adjusted EPS Of $4.34-$4.59 Vs $4.54 Estimate

Xcel Energy Reaffirms FY24 EPS Guidance Of $3.50 - $3.60 Vs. $3.57 Estimate

Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.80 by 10 percent. The company reported quarterly sales of $3.649 billion which missed the analyst consensus estimate of $4.128 billion by 11.61 percent. This is a 10.56 percent decrease over sales of $4.080 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

Xcel Energy Q1 2024 GAAP EPS $0.88 Beats $0.80 Estimate, Sales $3.649B Miss $4.128B Estimate

WIIM

Ford Motor Company shares are trading higher after the company reported better-than-expected Q1 financial results.

EQNR

Equinor shares are trading higher following better-than-expected Q1 financial results.

Health Care

General

West Pharmaceutical Services Raises Full-year 2024 Adjusted EPS Guidance To $7.63-$7.88, Compared Prior Range Of $7.50-$7.75 Versus Consensus Of $7.63

Sanofi shares are trading higher following better-than-expected Q1 financial results.

AstraZeneca shares are trading higher following a Q1 revenue beat.

TABLE 1: FULL-YEAR 2024 GUIDANCE2
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Previous Guidance
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Current Guidance
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Sales
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$38.1B - $38.9B
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$38.1B - $38.9B
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Organic1 Growth
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
4% - 6%
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
4% - 6%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Segment Margin
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
23.0% - 23.3%
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
23.0% - 23.3%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Expansion
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Up 30 - 60 bps
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
Up 30 - 60 bps
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Earnings Per Share3
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$9.80 - $10.10
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$9.80 - $10.10
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Adjusted Earnings Growth3
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
7% - 10%
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
7% - 10%
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Operating Cash Flow
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$6.7B - $7.1B
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$6.7B - $7.1B
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Free Cash Flow1
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$5.6B - $6.0B
</td>
<td colspan="1" rowspan="1">
			&nbsp;</td>
<td colspan="1" rowspan="1">
$5.6B - $6.0B
</td>
</tr>
</tbody>
</table>

Honeywell Reiterates FY2024 Outlook: Adj EPS $9.80-10.10 vs $9.95 Est; Sees Sales $38.100B-38.900B vs $38.48B Est

Unilever shares are trading higher following Q1 earnings.

Southside Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBSI#NASDAQ">SBSI</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.68 by 4.41 percent. This is a 14.46 percent decrease over earnings of $0.83 per share from the same period last year. The company reported quarterly sales of $63.072 million which missed the analyst consensus estimate of $67.725 million by 6.87 percent. This is a 3.54 percent decrease over sales of $65.386 million the same period last year.

SBSI

Southside Bancshares Q1 2024 GAAP EPS $0.71 Beats $0.68 Estimate, Sales $63.072M Miss $67.725M Estimate

Sanjay will remain with WNS in an advisory role until April 24, 2025 to help ensure a seamless transition.

Management

WNS Names Arijit Sen, Its Corporate Financial Controller, As CFO Effective July 25, 2024, Succeeding Sanjay Puria Who Has Chosen To Step Down For Family Reasons

West Pharmaceutical Services Reaffirms Full-Year 2024 Net Sales Guidance Of $3B-$3.025B Versus Consensus Of $3.01B

Tri Pointe Homes Sees Q2 Deliveries 1,500-1,600 Homes At Avg. Sales Price $670K-$680K

Oshkosh Raises FY24 Adj. EPS Outlook To Be In The Range Of $11.25 vs $10.36 Est.

FirstCash Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCFS#NASDAQ">FCFS</a>) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.52 by 1.97 percent. This is a 24 percent increase over earnings of $1.25 per share from the same period last year. The company reported quarterly sales of $836.370 million which missed the analyst consensus estimate of $846.074 million by 1.15 percent. This is a 9.65 percent increase over sales of $762.739 million the same period last year.

FCFS

FirstCash Hldgs Q1 2024 Adj EPS $1.55 Beats $1.52 Estimate, Sales $836.370M Miss $846.074M Estimate

The&nbsp;total consideration of up to &euro;275 million, consisting of an upfront cash payment of &euro;190 million and up to &euro;85 million in potential earnout payments based on the Rare Diseases business achieving certain sales milestones.&nbsp;
Following the information and consultation process with HRA Pharma Works Council in&nbsp;France, Perrigo would be able to exercise the put option granted by ESTEVE and enter into a definitive agreement with ESTEVE for the sale of the Rare Diseases business. The proposed final transaction is expected to close during the&nbsp;third quarter&nbsp;of 2024

Asset Sales

PRGO

Perrigo Secures Binding Offer To Divest Its HRA Pharma Rare Diseases Business For Up To €275M

Honeywell Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) reported quarterly earnings of $2.25 per share which beat the analyst consensus estimate of $2.17 by 3.69 percent. This is a 1.35 percent increase over earnings of $2.22 per share from the same period last year. The company reported quarterly sales of $9.105 billion which beat the analyst consensus estimate of $9.030 billion by 0.83 percent. This is a 2.72 percent increase over sales of $8.864 billion the same period last year.

Honeywell Intl Q1 2024 Adj EPS $2.25 Beats $2.17 Estimate, Sales $9.105B Beat $9.030B Estimate

Willis Towers Watson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>) reported quarterly earnings of $3.29 per share which beat the analyst consensus estimate of $3.24 by 1.54 percent. The company reported quarterly sales of $2.341 billion which missed the analyst consensus estimate of $2.373 billion by 1.37 percent. This is a 4.32 percent increase over sales of $2.244 billion the same period last year.